Supporting early phase clinical trials for heart, lung, blood, and sleep disorders in both adults and children, with applicants expected to be ready to start trials within the initial project period.
Supporting essential pilot studies for NHLBI clinical trials, aiming to inform Phase II-IV trial planning for heart, lung, blood, and sleep disorders.
NHLBI plans to fund single-site clinical trials (R61/R33) testing therapeutic, behavioral, or prevention strategies, encouraging innovative designs.
NIH plans a milestone-driven award supporting planning and early to definitive clinical trials across biomedical and other interventions for up to 7 years; applications are not yet being accepted.
NHLBI Catalyze funds early-stage medical device prototypes, disease target ID, & assay development for heart, lung, blood, & sleep disorders, aiming to prep projects for further testing.